Glikmann G, Moynihan M, Petersen I, Vestergaard B F
Dev Biol Stand. 1983;55:199-208.
A double antibody sandwich-ELISA has been developed for the detection of antigenic differences between wild and vaccine derived strains of Poliovirus type 1. Poliovirus strains antibodies were prepared in rabbits by immunization with virus suspensions of: Sabin LSc2ab (vaccine derived) and Brunhilde and Mahoney (wild types). IgG fractions were purified from antiserum by precipitation with ammonium sulphate and DEAE-Sephadex A50 chromatography. Purified IgG antibodies were used for coating of microtest plates (catching antibodies). The same reagents labeled with horseradish peroxidase were used as conjugates (detecting antibodies). Detecting antibodies were made strain specific by cross-absorption with the heterologous virus strain. Absorbed and non-absorbed detecting antibodies were subsequently used for detection and quantitation of the poliovirus antigen(s) bound to IgG-coated surfaces. Poliovirus laboratory strains and isolates from sixty-six individuals were differentiated intratypically as vaccine derived or wild types when the ELISA was performed using absorbed conjugates. No intermediate strains were found, and all clinical samples tested fell in two distinct categories. Conversely, when detecting antibodies were used before absorption a high degree of homology between wild and vaccine strains was demonstrated and the differentiation between the two groups was poorly achieved. The ELISA has been optimized in terms of specificity and sensitivity. Less than 10 ng of poliovirus antigens could be detected by non-absorbed detecting antibodies whereas 18 ng was the minimal amount detected by the same antibodies after absorption. Preparation of strain specific antibodies did not require a previous concentration of the poliovirus suspension used for the absorption. It is proposed that the developed ELISA is capable of: 1) detection of low amounts of poliovirus antigens in clinical samples, and 2) intratypic differentiation of poliovirus antigens as either vaccine derived or wild types.
已开发出一种双抗体夹心酶联免疫吸附测定法(ELISA),用于检测1型脊髓灰质炎病毒野生株和疫苗衍生株之间的抗原差异。通过用以下病毒悬液免疫兔子来制备脊髓灰质炎病毒株抗体:Sabin LSc2ab(疫苗衍生株)以及Brunhilde和Mahoney(野生株)。通过硫酸铵沉淀和DEAE-葡聚糖A50柱色谱法从抗血清中纯化IgG组分。纯化的IgG抗体用于包被微量测试板(捕获抗体)。用辣根过氧化物酶标记的相同试剂用作结合物(检测抗体)。通过与异源病毒株交叉吸收使检测抗体具有株特异性。随后使用吸收和未吸收的检测抗体来检测和定量与IgG包被表面结合的脊髓灰质炎病毒抗原。当使用吸收后的结合物进行ELISA检测时,脊髓灰质炎病毒实验室株和来自66个人的分离株在型内被区分为疫苗衍生株或野生株。未发现中间株,并且所有测试的临床样本都分为两个不同的类别。相反,当在吸收前使用检测抗体时,野生株和疫苗株之间显示出高度同源性,并且两组之间的区分效果不佳。该ELISA在特异性和灵敏度方面已得到优化。未吸收检测抗体可检测到少于10 ng的脊髓灰质炎病毒抗原,而吸收后相同抗体检测到的最小量为18 ng。制备株特异性抗体不需要预先浓缩用于吸收的脊髓灰质炎病毒悬液。建议所开发的ELISA能够:1)检测临床样本中少量的脊髓灰质炎病毒抗原,以及2)将脊髓灰质炎病毒抗原在型内区分为疫苗衍生株或野生株。